Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses

Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses

Thumbnail Image
Download
Name

nihms952466.pdf

Description
Accepted version
Size

2.49 MB

Format

Unknown

Checksum (MD5)

c57fbdcd85e2770d5cedc92558bd3e96

sword-2019-10-02T12:46:22.original.xml (130 B)
Original SWORD entry document
Author(s)
Cho, Jang Hwan
•
Collins, James J.
•
Wong, Wilson W
Date Issued
2018
Journal
Cell
Publisher
Elsevier BV
Version
Author's final manuscript
Abstract
© 2018 Elsevier Inc. T cells expressing chimeric antigen receptors (CARs) are promising cancer therapeutic agents, with the prospect of becoming the ultimate smart cancer therapeutics. To expand the capability of CAR T cells, here, we present a split, universal, and programmable (SUPRA) CAR system that simultaneously encompasses multiple critical “upgrades,” such as the ability to switch targets without re-engineering the T cells, finely tune T cell activation strength, and sense and logically respond to multiple antigens. These features are useful to combat relapse, mitigate over-activation, and enhance specificity. We test our SUPRA system against two different tumor models to demonstrate its broad utility and humanize its components to minimize potential immunogenicity concerns. Furthermore, we extend the orthogonal SUPRA CAR system to regulate different T cell subsets independently, demonstrating a dually inducible CAR system. Together, these SUPRA CARs illustrate that multiple advanced logic and control features can be implemented into a single, integrated system. A chimeric antigen receptor system that can integrate signals from multiple antigens and fine-tune T cell activation in a cell-type-specific manner holds promise for enhancing the safety and specificity of CAR T cell therapies for cancer treatment.
MIT Department
Massachusetts Institute of Technology. Synthetic Biology Center
Massachusetts Institute of Technology. Institute for Medical Engineering & Science
Massachusetts Institute of Technology. Department of Biological Engineering
Harvard University--MIT Division of Health Sciences and Technology
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
http://creativecommons.org/licenses/by-nc-nd/4.0/
Persistent DSpace Link
https://hdl.handle.net/1721.1/135450.2
DOI of Published Version
https://doi.org/10.1016/J.CELL.2018.03.038
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.